Search
09/07/2024
Single cell RNA sequencing of human FAPs reveals different functional stages in Duchenne muscular dystrophy
Fernández-Simón, E, Piñol-Jurado, P, Gokul-Nath, R, Unsworth, A, Alonso-Pérez, J, Schiava, M, Nascimento, A, Tasca, G, Queen, R, Cox, D, Suarez-Calvet, X, Díaz-Manera, J. Single cell RNA sequencing of human FAPs reveals different functional stages in Duchenne muscular dystrophy. Frontiers in Cell and Developmental Biology. 2024; 12DOI:10.3389/fcell.2024.1399319. PMID:39045456. IF:4.300(Q1/1D).
01/04/2026
Pathogenic or Likely Pathogenic GRN Variants Are Found in 0.1% of Parkinson's Disease Patients
Ganoza, CA, Westenberger, A, Paul, JJ, Curado, F, Rennecke, J, Mannepalli, S, Zonic, E, Saravanakumar, D, Paknia, O, Al-Ali, R, Laabs, B, Csoti, I, Valzania, F, Vandenberghe, W, Reetz, K, Afshari, M, Hassin-Baer, S, Fonoff, ET, Gruber, D, de Rosa, A, Musacchio, T, Aguiar, PD, Negrotti, A, Tumas, V, Gomez-Esteban, JC, Gurevich, T, Pavese, N, Kulisevsky, J, Sammler, E, Klein, C, Bauer, P, Beetz, C. Pathogenic or Likely Pathogenic GRN Variants Are Found in 0.1% of Parkinson's Disease Patients. MOVEMENT DISORDERS. 2026; 41(4)DOI:10.1002/mds.70161. PMID:41439479. IF:7.600(Q1/1D).
01/06/2026
Advancing the Treatment of Motor Fluctuations in Parkinson's Disease with a Next-Generation Levodopa/Carbidopa Formulation
Stocchi, F, Knecht, M, Marjanovic, I, Wach, A, Kopra, J, Kulisevsky, J. Advancing the Treatment of Motor Fluctuations in Parkinson's Disease with a Next-Generation Levodopa/Carbidopa Formulation. Neurology and Therapy. 2026; 15(3)DOI:10.1007/s40120-026-00898-z. PMID:41724884. IF:4.800(Q1/2D).
31/01/2026
Ten-year population-based assessment of multimorbidity burden progression in a regional cohort of 5.5 million adults
Valero-Bover, D, Monterde, D, Carot-Sans, G, Vela, E, González-Colom, R, Roca, J, Pontes, C, Michelena, X, Nogueras, MM, Aparicio, P, Corrales, I, Biec, T, Cano, I, Piera-Jiménez, J. Ten-year population-based assessment of multimorbidity burden progression in a regional cohort of 5.5 million adults. npj Digital Medicine. 2026; 9(1)DOI:10.1038/s41746-026-02395-x. PMID:41620560. IF:15.100(Q1/1D).
07/05/2026
The role of Spanish clinical pharmacologists in economic evaluations of health technologies
Delgado-Espinoza, CE, Antonijoan, RM, Martínez-Zapata, MJ. The role of Spanish clinical pharmacologists in economic evaluations of health technologies. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2026; 82(6)DOI:10.1007/s00228-026-04070-2. PMID:42091708. IF:2.700(Q2/5D).
14/03/2024
Prevalence of use of on-label and off-label psychotropics in the Greek pediatric population
Pesiou, S, Barcelo, R, Papazisis, G, Torres, F, Pontes, C. Prevalence of use of on-label and off-label psychotropics in the Greek pediatric population. Frontiers in Pharmacology. 2024; 15DOI:10.3389/fphar.2024.1348887. PMID:38549664. IF:4.800(Q1/2D).
01/05/2026
Low-intervention clinical trials in Spain: Do they progress?
Delgado-Espinoza, CE, Pestana, MJC, Amaro, K, Antonijoan, RM, Pontes, C. Low-intervention clinical trials in Spain: Do they progress?. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2026; 92(5)DOI:10.1002/bcp.70409. PMID:41406957. IF:3.000(Q2/4D).
01/01/2025
Comment on the article 'Misinformation about interchangeable biosimilars'
Cohen, HP, Pontes, C, de Mora, F. Comment on the article 'Misinformation about interchangeable biosimilars'. Gabi Journal-Generics And Biosimilars Initiative Journal. 2025; 14(1)DOI:10.5639/gabij.2025.1401.003. PMID:. IF:(Q/D).